Julianna Archibald sits with her siblings Josiah Archibald, Mason Archibald, and Elijah Phillips, all three of whom have Barth syndrome. Josanne Archibald/Handout via REUTERS
Today's recommended read is an exclusive from my colleague Patrick Wingrove. He reports on the US FDA approving a pricey rare disease drug despite findings by its data reviewers that the treatment, while safe, was no more effective than a placebo.
The Food and Drug Administration on September 19 gave its backing to Stealth Biotherapeutics' elamipretide, which will be sold as Forzinity and priced at up to nearly $800,000 a year, although FDA documents show nearly a dozen reviewers recommended against approval.
Reuters One Essential Read is sent three days a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.
Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here.
This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement.
